Roche signs $1.53bn global licensing deal for Simcere's B-cell antibody SIM0660
The agreement gives Roche exclusive global rights to develop, manufacture and commercialise Simcere Zaiming's investigational trispecific antibody SIM0660 outside Greater China.
Roche has entered into a global licensing agreement for SIM0660, an investigational CD79a/CD19/CD3 trispecific antibody being developed by Simcere Zaiming for B-cell malignancies and autoimmune diseases.
Simcere is eligible to receive up to $1.53 billion under the agreement, including a $75 million upfront payment, development and commercial milestone payments and tiered royalties on future sales.
Field | Content |
Alert Type | Deal |
Companies | Roche; Simcere Zaiming |
Deal Type | Exclusive licensing agreement |
Asset or Company | SIM0660 |
Therapy Area(s) | B-cell malignancies; autoimmune diseases |
Technology or Modality | CD79a/CD19/CD3 trispecific antibody |
Deal Value | Up to $1.53 billion, including $75 million upfront plus potential development and commercial milestone payments; Simcere is also eligible for tiered royalties on future sales |
Development Stage | Clinical-stage |
Geography | Global rights outside Greater China |
What Happened | Roche secured exclusive rights outside Greater China to develop, manufacture and commercialise SIM0660, Simcere Zaiming's investigational CD79a/CD19/CD3 trispecific antibody. |
Why It Matters | The agreement adds a differentiated B-cell-targeting programme to Roche's pipeline with potential applications across both haematological malignancies and autoimmune diseases. |
Supporting Context | SIM0660 is designed to engage CD3-positive T cells while targeting CD79a and CD19 on B cells, providing a dual B-cell-targeting approach. |
Strategic Rationale | The licence gives Roche access to a potentially differentiated B-cell-directed therapy while allowing Simcere to retain rights in Greater China. |
Potential Impact | Successful development could broaden therapeutic options for diseases driven by pathogenic or malignant B cells. |
Key Takeaway | Roche is committing up to $1.53 billion to secure global rights outside Greater China to Simcere's trispecific B-cell antibody SIM0660. |
What to Watch | Further clinical development of SIM0660 and progress across its oncology and autoimmune indications. |
Primary Source | Simcere Pharmaceutical Group |
Relevant Date | 1 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare